These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 10449779

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
    Dhar A, Hu J, Reeves R, Resar LM, Colburn NH.
    Oncogene; 2004 May 27; 23(25):4466-76. PubMed ID: 15064752
    [Abstract] [Full Text] [Related]

  • 3. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
    Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR, Young MR, Colburn NH.
    Cancer Res; 2007 Mar 15; 67(6):2430-8. PubMed ID: 17363560
    [Abstract] [Full Text] [Related]

  • 4. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.
    Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, Colburn NH.
    Mol Carcinog; 1997 Jul 15; 19(3):204-12. PubMed ID: 9254887
    [Abstract] [Full Text] [Related]

  • 5. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH.
    Oncogene; 1998 May 28; 16(21):2711-21. PubMed ID: 9652737
    [Abstract] [Full Text] [Related]

  • 6. Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes.
    Li JJ, Cao Y, Young MR, Colburn NH.
    Mol Carcinog; 2000 Nov 28; 29(3):159-69. PubMed ID: 11108661
    [Abstract] [Full Text] [Related]

  • 7. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
    Jansen AP, Colburn NH, Verma AK.
    Oncogene; 1999 Oct 14; 18(42):5806-13. PubMed ID: 10523861
    [Abstract] [Full Text] [Related]

  • 8. c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation.
    Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E, Colburn NH.
    Mol Carcinog; 1995 May 14; 13(1):27-36. PubMed ID: 7766308
    [Abstract] [Full Text] [Related]

  • 9. bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells.
    Amstad PA, Liu H, Ichimiya M, Chang S, Berezesky IK, Trump BF.
    Mol Carcinog; 1997 Oct 14; 20(2):231-9. PubMed ID: 9364213
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
    Li JJ, Dong Z, Dawson MI, Colburn NH.
    Cancer Res; 1996 Feb 01; 56(3):483-9. PubMed ID: 8564958
    [Abstract] [Full Text] [Related]

  • 11. Gene regulation and genetic susceptibility to neoplastic transformation: AP-1 and p80 expression in JB6 cells.
    Bernstein LR, Ben-Ari ET, Simek SL, Colburn NH.
    Environ Health Perspect; 1991 Jun 01; 93():111-9. PubMed ID: 1773784
    [Abstract] [Full Text] [Related]

  • 12. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation.
    Gu Q, Tan M, Sun Y.
    Cancer Res; 2007 Apr 15; 67(8):3616-25. PubMed ID: 17440073
    [Abstract] [Full Text] [Related]

  • 13. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
    Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, Colburn NH.
    Oncogene; 1998 Dec 31; 17(26):3493-8. PubMed ID: 10030673
    [Abstract] [Full Text] [Related]

  • 14. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.
    Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH.
    Proc Natl Acad Sci U S A; 1994 Jan 18; 91(2):609-13. PubMed ID: 8290571
    [Abstract] [Full Text] [Related]

  • 15. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.
    Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH.
    Cancer Res; 2001 May 15; 61(10):4160-8. PubMed ID: 11358840
    [Abstract] [Full Text] [Related]

  • 16. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model.
    Cooper SJ, MacGowan J, Ranger-Moore J, Young MR, Colburn NH, Bowden GT.
    Mol Cancer Res; 2003 Sep 15; 1(11):848-54. PubMed ID: 14517347
    [Abstract] [Full Text] [Related]

  • 17. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion.
    Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT.
    Cancer Res; 2002 Jun 01; 62(11):3044-7. PubMed ID: 12036911
    [Abstract] [Full Text] [Related]

  • 18. Differential inhibition of UVB-induced AP-1 and NF-kappaB transactivation by components of the jun bZIP domain.
    Cooper S, Ranger-Moore J, Bowden TG.
    Mol Carcinog; 2005 Jun 01; 43(2):108-16. PubMed ID: 15791649
    [Abstract] [Full Text] [Related]

  • 19. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
    Suzukawa K, Colburn NH.
    Oncogene; 2002 Mar 28; 21(14):2181-90. PubMed ID: 11948401
    [Abstract] [Full Text] [Related]

  • 20. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.
    Liu G, Bode A, Ma WY, Sang S, Ho CT, Dong Z.
    Cancer Res; 2001 Aug 01; 61(15):5749-56. PubMed ID: 11479211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.